vs
Aligos Therapeutics, Inc.（ALGS）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Aligos Therapeutics, Inc.的58378.7倍（$9.9B vs $169.0K）。安进净利率更高（13.5% vs -11763.9%，领先11777.4%）。安进同比增速更快（8.6% vs -72.1%）。过去两年安进的营收复合增速更高（15.1% vs -50.7%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ALGS vs AMGN — 直观对比
营收规模更大
AMGN
是对方的58378.7倍
$169.0K
营收增速更快
AMGN
高出80.7%
-72.1%
净利率更高
AMGN
高出11777.4%
-11763.9%
两年增速更快
AMGN
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $9.9B |
| 净利润 | $-19.9M | $1.3B |
| 毛利率 | — | 69.8% |
| 营业利润率 | -12907.7% | 27.6% |
| 净利率 | -11763.9% | 13.5% |
| 营收同比 | -72.1% | 8.6% |
| 净利润同比 | 75.8% | 112.6% |
| 每股收益（稀释后） | $4.23 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSAMGN
| Q4 25 | $169.0K | $9.9B | ||
| Q3 25 | $741.0K | $9.6B | ||
| Q2 25 | $965.0K | $9.2B | ||
| Q1 25 | $311.0K | $8.1B | ||
| Q4 24 | $606.0K | $9.1B | ||
| Q3 24 | $1.3M | $8.5B | ||
| Q2 24 | $1.1M | $8.4B | ||
| Q1 24 | $694.0K | $7.4B |
净利润ALGSAMGN
| Q4 25 | $-19.9M | $1.3B | ||
| Q3 25 | $-31.5M | $3.2B | ||
| Q2 25 | $-15.9M | $1.4B | ||
| Q1 25 | $43.1M | $1.7B | ||
| Q4 24 | $-82.2M | $627.0M | ||
| Q3 24 | $-19.3M | $2.8B | ||
| Q2 24 | $5.1M | $746.0M | ||
| Q1 24 | $-34.9M | $-113.0M |
毛利率ALGSAMGN
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | 57.0% |
营业利润率ALGSAMGN
| Q4 25 | -12907.7% | 27.6% | ||
| Q3 25 | -3827.4% | 26.4% | ||
| Q2 25 | -1924.0% | 28.9% | ||
| Q1 25 | -6187.5% | 14.5% | ||
| Q4 24 | -3393.2% | 25.4% | ||
| Q3 24 | -1610.5% | 24.1% | ||
| Q2 24 | -2489.5% | 22.8% | ||
| Q1 24 | -3176.7% | 13.3% |
净利率ALGSAMGN
| Q4 25 | -11763.9% | 13.5% | ||
| Q3 25 | -4256.0% | 33.7% | ||
| Q2 25 | -1643.8% | 15.6% | ||
| Q1 25 | 13854.7% | 21.2% | ||
| Q4 24 | -13556.1% | 6.9% | ||
| Q3 24 | -1540.7% | 33.3% | ||
| Q2 24 | 477.0% | 8.9% | ||
| Q1 24 | -5023.5% | -1.5% |
每股收益（稀释后）ALGSAMGN
| Q4 25 | $4.23 | $2.45 | ||
| Q3 25 | $-3.04 | $5.93 | ||
| Q2 25 | $-1.53 | $2.65 | ||
| Q1 25 | $-2.11 | $3.20 | ||
| Q4 24 | $-13.10 | $1.17 | ||
| Q3 24 | $-3.07 | $5.22 | ||
| Q2 24 | $0.81 | $1.38 | ||
| Q1 24 | $-5.58 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $9.1B |
| 总债务越低越好 | — | $54.6B |
| 股东权益账面价值 | $53.5M | $8.7B |
| 总资产 | $88.5M | $90.6B |
| 负债/权益比越低杠杆越低 | — | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ALGSAMGN
| Q4 25 | $77.8M | $9.1B | ||
| Q3 25 | $99.1M | $9.4B | ||
| Q2 25 | $122.9M | $8.0B | ||
| Q1 25 | $137.9M | $8.8B | ||
| Q4 24 | $56.9M | $12.0B | ||
| Q3 24 | $74.9M | $9.0B | ||
| Q2 24 | $94.5M | $9.3B | ||
| Q1 24 | $112.7M | $9.7B |
总债务ALGSAMGN
| Q4 25 | — | $54.6B | ||
| Q3 25 | — | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | — | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ALGSAMGN
| Q4 25 | $53.5M | $8.7B | ||
| Q3 25 | $71.8M | $9.6B | ||
| Q2 25 | $101.9M | $7.4B | ||
| Q1 25 | $116.4M | $6.2B | ||
| Q4 24 | $-29.0M | $5.9B | ||
| Q3 24 | $50.1M | $7.5B | ||
| Q2 24 | $67.2M | $5.9B | ||
| Q1 24 | $59.8M | $5.0B |
总资产ALGSAMGN
| Q4 25 | $88.5M | $90.6B | ||
| Q3 25 | $109.8M | $90.1B | ||
| Q2 25 | $134.7M | $87.9B | ||
| Q1 25 | $150.7M | $89.4B | ||
| Q4 24 | $70.1M | $91.8B | ||
| Q3 24 | $88.4M | $90.9B | ||
| Q2 24 | $108.8M | $90.9B | ||
| Q1 24 | $127.9M | $93.0B |
负债/权益比ALGSAMGN
| Q4 25 | — | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | — | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | — | $961.0M |
| 自由现金流率自由现金流/营收 | — | 9.7% |
| 资本支出强度资本支出/营收 | — | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | — | $8.1B |
8季度趋势，按日历期对齐
经营现金流ALGSAMGN
| Q4 25 | $-21.7M | $1.6B | ||
| Q3 25 | $-24.3M | $4.7B | ||
| Q2 25 | $-15.5M | $2.3B | ||
| Q1 25 | $-20.9M | $1.4B | ||
| Q4 24 | $-18.4M | $4.8B | ||
| Q3 24 | $-20.1M | $3.6B | ||
| Q2 24 | $-19.5M | $2.5B | ||
| Q1 24 | $-22.7M | $689.0M |
自由现金流ALGSAMGN
| Q4 25 | — | $961.0M | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $980.0M | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $459.0M |
自由现金流率ALGSAMGN
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 44.4% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | — | 12.0% | ||
| Q4 24 | — | 48.4% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 26.5% | ||
| Q1 24 | — | 6.2% |
资本支出强度ALGSAMGN
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.1% |
现金转化率ALGSAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | -0.49× | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | -3.85× | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGS
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
